insulin glargine 300 U/ml (Gla�300)	insulin glargine 100 U/ml (Gla�100)	number of nocturnal or severe hypoglycaemic events	15492	15666	There was a significant 37% relative reduction in annualized rate with Gla‐300 compared with Gla‐100 [1.74 vs 2.77, rate ratio 0.63 (95% CI 0.42–0.96); p = 0.0308; Figure 3B]
insulin glargine 300 U/ml (Gla�300)	insulin glargine 100 U/ml (Gla�100)	at least one hypoglycaemic event during 12 months of treatment	16716	16933	The annualized event rate (Figure 3D) and the percentage of participants with at least one event during 12 months of treatment were numerically lower but not significantly different with Gla‐300 compared with Gla‐100.
insulin glargine 300 U/ml (Gla�300)	insulin glargine 100 U/ml (Gla�100)	percentage of participants experiencing ≥1 nocturnal confirmed or severe hypoglycaemic event during the 12�month	15493	15886	here was a significant 37% relative reduction in annualized rate with Gla‐300 compared with Gla‐100 [1.74 vs 2.77, rate ratio 0.63 (95% CI 0.42–0.96); p = 0.0308; Figure 3B], and a 16% relative risk reduction in the percentage of participants experiencing ≥1 nocturnal confirmed or severe hypoglycaemic event during the 12‐month study period [38% vs 45%, relative risk 0.84 (95% CI 0.71–0.99);
insulin glargine 300 U/ml (Gla�300)	insulin glargine 100 U/ml (Gla�100)	number of nocturnal or severe hypoglycaemic events	1295	1528	A significant relative reduction of 37% in the annualized rate of nocturnal confirmed [≤3.9 mmol/l (≤70 mg/dl)] or severe hypoglycaemia was observed with Gla‐300 compared with Gla‐100: rate ratio 0.63 [(95% CI 0.42–0.96); p = 0.031],
insulin glargine 300 U/ml (Gla�300)	insulin glargine 100 U/ml (Gla�100)	percentage of participants experiencing ≥1 nocturnal confirmed or severe hypoglycaemic event during the 12�month	-1	-1	There was a significant 37% relative reduction in annualized rate with Gla�300 compared with Gla�100 [1.74 vs 2.77, rate ratio 0.63 (95% CI 0.42–0.96); p = 0.0308; Figure 3B], and a 16% relative risk reduction in the percentage of participants experiencing ≥1 nocturnal confirmed or severe hypoglycaemic event during the 12�month study period [38% vs 45%, relative risk 0.84 (95% CI 0.71–0.99); Table S1].
insulin glargine 300 U/ml (Gla�300)	insulin glargine 100 U/ml (Gla�100)	weight	1651	1775	Weight gain was significantly lower with Gla‐300 than Gla‐100 [LS mean difference −0.7 (95% CI −1.3 to −0.2) kg; p = 0.009].
insulin glargine 300 U/ml (Gla�300)	insulin glargine 100 U/ml (Gla�100)	weight	-1	-1	The mean (s.d.) change in body weight, based on the last on�treatment value, was significantly lower with Gla�300 than with Gla�100 [0.4 (4.1) vs 1.2 (3.6) kg];
insulin glargine 300 U/ml (Gla�300)	insulin glargine 100 U/ml (Gla�100)	adverse events	1776	1913	Both treatments were well tolerated with a similar pattern of adverse events (incidence of 69 and 60% in the Gla‐300 and Gla‐100 groups).
